ADAPT-BLADDER
Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder
- NCT03317158 ↗
- Active, not recruiting
- Noah Hahn, M.D.
- Standard
We haven't built an HCP commentary report on ADAPT-BLADDER (durvalumab plus gemcitabine plus docetaxel; durvalumab plus tremelimumab plus gemcitabine plus docetaxel; intravesical NAI plus gemcitabine plus docetaxel in BCG-unresponsive, BCG-relapsing, high-risk BCG-naive non-muscle invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on ADAPT-BLADDER so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 10 | |
| Podcasts | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- PhAse 1/2 StuDy of Modern ImmunotherApy in BCG-Unresponsive, BCG-RelaPsing, and High-Risk BCG-Naive Non-muscle Invasive UroThelial Carcinoma of the BLADDER
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Urothelial Carcinoma; Bladder Cancer
- Interventions
- Durvalumab (Cohort 1-3); External Beam Radiotherapy (EBRT); Bacillus Calmette-Guérin (BCG); Gemcitabine; Docetaxel; Tremelimumab; Durvalumab (Cohort 4/5); To be determined; Intravesical NAI (Cohorts 6-7); Subcutaneous NAI (Cohort 8)
- Arms
- Phase 1: Cohort 1 · Experimental
- Phase 1: Cohort 2 · Experimental
- Phase 1: Cohort 3 · Experimental
- Phase 1: Cohort 4 · Experimental
- Phase 1: Cohort 5 · Experimental
- Phase 1: Cohort 6 · Experimental
- Phase 2: Cohort 4 Expansion · Experimental
- Phase 1: Cohort 7 · Experimental
- Phase 1: Cohort 8 · Experimental
- Phase 1: Cohort 9 · Experimental
- Enrollment
- 186 (estimated)
- Primary outcomes
- Phase 1: Determine the recommended phase 2 dose (RP2D) from BCG-unresponsive non-muscle invasive bladder cancer (NMIBC)
- Phase 2: Determine the complete response rate within individual phase 2 expansion cohorts of BCG-unresponsive, BCG-relapsing/persistent, and high-risk BCG-naïve NMIBC subjects treated with each study regimen
- Sponsor
- Noah Hahn, M.D. with AstraZeneca, Hoosier Cancer Research Network, ImmunityBio, Inc.
- Start
- Nov 21, 2017
- Primary completion
- Dec 31, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03317158 · updated Jul 15, 2026